Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    Chemotherapy Contributes to Cognitive Difficulties in Older Adults, Even After Treatment Ends: Presented at AAGP - (DGDispatch)
    Fluorodeoxyglucose-PET May Identify Occult Metastases: Presented at ASCO-GU - (DGDispatch)
    Paclitaxel, Cisplatin, Gemcitabine Combination Safe, Effective for Male Germ Cell Tumours: Presented at ASCO-GU - (DGDispatch)
    Hyperthermic Intraperitoneal Chemotherapy Thwarts Recurrent Ascites From Appendiceal Cancer: Presented at SSO - (DGDispatch)
    High-Dose Sequential Chemo Does Not Improve Outcomes in Poor-Prognosis Germ Cell Tumours: Presented at ASCO-GU - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
    • Expanding Treatment Options for Relapsed/Refractory Follicular Lymphoma
    • Improving Clinical Standards in Relapsed/Refractory Follicular Lymphoma
    • Exploring New Directions in the Management of Relapsed/Refractory FL
    • Skin Cancer Update
      Human Papillomavirus-Related Anal Squamous Cell Dysplasia and Carcinoma in HIV Infection

      Webcasts/CME archive

       Recent cases - Oncology Other
        Neoadjuvant Radiotherapy Of Primary Irresectable Unicentric Castleman's Disease: A Case Report And Review Of The Literature
        Transient Bilateral Abducens Neuropathy With Post-Tetanic Facilitation And Acute Hypokalemia Associated With Oxaliplatin: A Case Report
        A Retroperitoneal Mass With Elevated Alpha-1-Fetoprotein: Not Always A Testicular Carcinoma
        A Case Report Of Pseudoprogression Followed By Complete Remission After Proton-Beam Irradiation For A Low-Grade Glioma In A Teenager: The Value Of Dynamic Contrast-Enhanced MRI
        Rapid Palliation Of Symptoms With Platinum-Based Chemotherapy Plus Cetuximab In Recurrent Oral Cancer: A Case Report

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Pre-Operative Cisplatin/5-Fluorouracil Provides No Increase In Squamous Esophageal Cancer Survival

        A DGReview of :"The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil."
        Annals of Surgical Oncology

        10/24/2002
        By Elda Hauschildt


        Adjuvant chemotherapy with cisplatin and 5-fluorouracil infusion followed by surgery does not improve overall survival in patients with locally advanced squamous esophageal cancer.

        Chinese researchers compared pulse and continuous regimens in evaluating the two agents in 83 consecutive esophageal cancer patients between 1991 and 1997. They compared results with those of 76 historical control patients who received surgery only.

        Study participants underwent surgical exploration after completing two cycles of the cisplatin and 5-fluorouracil chemotherapy regimens. The regimens were delivered in either pulse or continuous infusion cycles.

        The investigators, from the Chinese University of Hong Kong in Hong Kong, note participants in both groups had similar demographic characteristics and tumour stages.

        Resection rates, operative morbidity, mortality and survival rates were included in the comparisons.

        Approximately 50 percent of patients receiving chemotherapy achieved partial response. No mortality was related to the chemotherapy regimens.

        The resection rate for the control patients was 71.1 percent and 82 percent for the preoperative chemotherapy patients. Morbidity was 51 percent in controls versus 55 percent in the chemotherapy patients. Mortality was 4 percent in the control patients and 10.8 percent in the chemotherapy patients.

        Median survival was 12 months in the control patients and 13.5 months in the chemotherapy patients.

        The researchers found no statistically significant differences between the two chemotherapy regimens.
        Annals of Surgical Oncology, 2002; 9: 617-624. "The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil."

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send